BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21454617)

  • 1. Entropy increases from different sources support the high-affinity binding of the N-terminal inhibitory domains of tissue inhibitors of metalloproteinases to the catalytic domains of matrix metalloproteinases-1 and -3.
    Wu Y; Wei S; Van Doren SR; Brew K
    J Biol Chem; 2011 May; 286(19):16891-9. PubMed ID: 21454617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thermodynamic Basis of Selectivity in the Interactions of Tissue Inhibitors of Metalloproteinases N-domains with Matrix Metalloproteinases-1, -3, and -14.
    Zou H; Wu Y; Brew K
    J Biol Chem; 2016 May; 291(21):11348-58. PubMed ID: 27033700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure.
    Batra J; Robinson J; Soares AS; Fields AP; Radisky DC; Radisky ES
    J Biol Chem; 2012 May; 287(19):15935-46. PubMed ID: 22427646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased backbone mobility in beta-barrel enhances entropy gain driving binding of N-TIMP-1 to MMP-3.
    Arumugam S; Gao G; Patton BL; Semenchenko V; Brew K; Van Doren SR
    J Mol Biol; 2003 Mar; 327(3):719-34. PubMed ID: 12634064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Directed evolution of the metalloproteinase inhibitor TIMP-1 reveals that its N- and C-terminal domains cooperate in matrix metalloproteinase recognition.
    Raeeszadeh-Sarmazdeh M; Greene KA; Sankaran B; Downey GP; Radisky DC; Radisky ES
    J Biol Chem; 2019 Jun; 294(24):9476-9488. PubMed ID: 31040180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein engineering of the tissue inhibitor of metalloproteinase 1 (TIMP-1) inhibitory domain. In search of selective matrix metalloproteinase inhibitors.
    Wei S; Chen Y; Chung L; Nagase H; Brew K
    J Biol Chem; 2003 Mar; 278(11):9831-4. PubMed ID: 12515831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constraining specificity in the N-domain of tissue inhibitor of metalloproteinases-1; gelatinase-selective inhibitors.
    Hamze AB; Wei S; Bahudhanapati H; Kota S; Acharya KR; Brew K
    Protein Sci; 2007 Sep; 16(9):1905-13. PubMed ID: 17660250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the binding of hydroxamic acid and carboxylic acid inhibitors to the stromelysin-1 (matrix metalloproteinase-3) catalytic domain by isothermal titration calorimetry.
    Parker MH; Lunney EA; Ortwine DF; Pavlovsky AG; Humblet C; Brouillette CG
    Biochemistry; 1999 Oct; 38(41):13592-601. PubMed ID: 10521266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystal structure of the catalytic domain of matrix metalloproteinase-1 in complex with the inhibitory domain of tissue inhibitor of metalloproteinase-1.
    Iyer S; Wei S; Brew K; Acharya KR
    J Biol Chem; 2007 Jan; 282(1):364-71. PubMed ID: 17050530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global orientation of bound MMP-3 and N-TIMP-1 in solution via residual dipolar couplings.
    Arumugam S; Van Doren SR
    Biochemistry; 2003 Jul; 42(26):7950-8. PubMed ID: 12834347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering minimal tissue inhibitors of metalloproteinase targeting MMPs via gene shuffling and yeast surface display.
    Hosseini A; Kumar S; Hedin K; Raeeszadeh-Sarmazdeh M
    Protein Sci; 2023 Dec; 32(12):e4795. PubMed ID: 37807423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational study of the amino-terminal domain of human tissue inhibitor of metalloproteinases 1 (TIMP-1) locates an inhibitory region for matrix metalloproteinases.
    Huang W; Meng Q; Suzuki K; Nagase H; Brew K
    J Biol Chem; 1997 Aug; 272(35):22086-91. PubMed ID: 9268350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of inductive effects of different concentrations of cyclosporine A on MMP-1, MMP-2, MMP-3, TIMP-1, and TIMP-2 in fetal and adult human gingival fibroblasts.
    Nazemisalman B; Sajedinejad N; Darvish S; Vahabi S; Gudarzi H
    J Basic Clin Physiol Pharmacol; 2019 Mar; 30(3):. PubMed ID: 30913036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinase-10/TIMP-2 structure and analyses define conserved core interactions and diverse exosite interactions in MMP/TIMP complexes.
    Batra J; Soares AS; Mehner C; Radisky ES
    PLoS One; 2013; 8(9):e75836. PubMed ID: 24073280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition.
    Lee MH; Rapti M; Knaüper V; Murphy G
    J Biol Chem; 2004 Apr; 279(17):17562-9. PubMed ID: 14734567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor.
    Fernandez-Catalan C; Bode W; Huber R; Turk D; Calvete JJ; Lichte A; Tschesche H; Maskos K
    EMBO J; 1998 Sep; 17(17):5238-48. PubMed ID: 9724659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinases and their inhibitors in gastric cancer.
    Murray GI; Duncan ME; Arbuckle E; Melvin WT; Fothergill JE
    Gut; 1998 Dec; 43(6):791-7. PubMed ID: 9824606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1' residue of substrate.
    Meng Q; Malinovskii V; Huang W; Hu Y; Chung L; Nagase H; Bode W; Maskos K; Brew K
    J Biol Chem; 1999 Apr; 274(15):10184-9. PubMed ID: 10187802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
    Baker EA; Bergin FG; Leaper DJ
    Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased acinar damage of salivary glands of patients with Sjögren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios.
    Pérez P; Kwon YJ; Alliende C; Leyton L; Aguilera S; Molina C; Labra C; Julio M; Leyton C; González MJ
    Arthritis Rheum; 2005 Sep; 52(9):2751-60. PubMed ID: 16142742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.